MedTrace Logo

Radioimmunoimaging of Light Chain (AL) Amyloidosis

NCT01815086 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-09-18

No results posted yet for this study

Summary

The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.

Conditions

  • AL Amyloidosis

Interventions

BIOLOGICAL

Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)

Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)

Sponsors & Collaborators

  • University of Tennessee

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01815086 on ClinicalTrials.gov